ABSTRACT Esmolol is a new ultra short-acting (half-life [tl/2½] 9 min) /3I-adrenergic-receptor antagonist reported to have no intrinsic sympathomimetic activity. The safety and efficacy of esmolol in lowering the ventricular rate and rate-pressure product in patients with acute myocardial infarction (n = 5), postmyocardial infarction angina (n = 10), or acute unstable angina (n = 4), and without cardiogenic shock were studied. After a 30 min observation period, esmolol was titrated to a maximum dose of 300 gg/kg/min and infused for up to 420 min. The ventricular rate fell from 92 ± 11 (mean SD) to 77 + 13 beats/min (p < .01) and the systolic arterial pressure decreased from 120 ± 13 to 97 11 mm Hg (p < .01) during the initial 30 min titration period. There was no significant change during the maintenance phase, and both the ventricular rate and arterial pressure returned rapidly toward baseline values within 30 min of termination of the infusion. The cardiac index fell from 2.8 + 0.6 to 2.2 ± 0.6 liters/min/m2 (p < .01) during the same period, and also returned to the baseline level 30 min after termination of the infusion. There was no significant change in the pulmonary capillary wedge pressure, respiratory rate, or PR interval. Five patients required termination of infusion because of hypotension and all recovered uneventfully within 30 min of stopping the esmolol. One patient required a brief infusion of dopamine to restore hemodynamic stability. This experience suggests that in the absence of _fongestive heart failure or shock, esmolol is effective in slowing the heart rate and lowering the arterial pressure and the rate-pressure product in patients with acute myocardial ischemia. Furthermore, the hemodynamic effects are rapidly reversed after termination of infusion. Thus, esmolol may be of value in patients with acute myocardial ischemia in whom rapid titration of /-adrenergic blockade is clinically desirable. Circulation 72, No. 4, 873-880, 1985. THE USE OF currently available ,(-adrenergic-blocking agents in the management of patients with acute myocardial ischemia frequently raises concern about the potential initiation or exacerbation of congestive heart failure, severe sinus bradycardia, advanced degrees of atrioventricular block, or bronchospasm. 13 The development of these adverse effects may be un- 
ases.* IU This short duration of action permits rapid titration during intravenous infusion to desired levels of 3-adrenergic blockade. In addition, the rapid disappearance of /3-blockade upon termination of infusion may allow ready reversal of side effects should they develop. Initial studies have demonstrated the safety and efficacy of esmolol in reducing the heart rate response to isoproterenol in animals and man, as well as for controlling the ventricular rate in patients with supraventricular tachycardia. [11] [12] [13] [14] In experimental studies esmolol has been shown to reduce myocardial ischemic damage. 14 THERAPY AND PREVENTION-/3-ADRENERGIC BLOCKADE tenance phases, as well as the heart rate 15 and 30 min after termination of the infusion. The peak effect on ventricular response was usually achieved at a dose of 150 gg/kg/min. Sixteen patients (group A) completed the titration phase and advanced to the maintenance phase at doses of 150 to 300 ,ug/kg/min (figure 2). The maintenance infusion lasted for 360 + 94 min (range 120 to 420). There was no clinically significant change in heart rate during the maintenance phase. Three patients (group B) entered the titration phase but did not advance to the maintenance phase and are discussed below. Thirty minutes after the esmolol infusion was stopped the mean heart rate returned to within 4% of baseline values in patients in groups A and B.
Hemodynamics. Arterial pressure at baseline in the 19 patients was (systolic/diastolic, mean) 120/72, 88 mm Hg, and fell to 97/63, 75 mm Hg, at the end of the titration period. These decreases averaged 15% (systolic), 19% (diastolic), and 16% (mean) of baseline values. There was no significant change in blood pressure during the maintenance phase and blood pressure returned to 110/69, 83 mm Hg, 30 min after the esmolol infusion was stopped. During recovery, pressures returned to averages of 93% (systolic), 94% (diastolic), and 94% (mean) of baseline levels (figure 3; lary wedge pressure recovered in less than 20 min after termination of esmolol and a brief infusion of dopamine. The other patient with an anterior AMI had tolerated the 300 ,ug/kg/min infusion for 90 min without difficulty when he suddenly developed a profound postprandial vagal episode with nausea, vomiting, and hypotension. All symptoms and signs resolved in less than 30 min after esmolol was discontinued and 25 mg of prochlorperazine was given by the rectal route. The limiting factor in the three patients (group B) who were unable to enter the maintenance phase was hypotension (systolic blood pressure fell below 90 mm Hg). Of these, two were evolving acute anterior infarctions at the time of the esmolol infusion and one subsequently died 48 hr later from cardiogenic shock. The third patient's systolic blood pressure fell below 90 mm Hg only at the 300 ,ug/kg/min dose. In each of these three patients blood pressure and heart rate both returned to control levels within 30 min of discontinuation of the esmolol infusion and none suffered any persistent sequelae as a result of transient hypotension. The time course of the recovery of heart rate and systolic pressure in these four patients with significant hypotension is depicted in figure 4 .
Pulmonary capillary wedge pressure was not significantly altered during esmolol infusion (table 2) .
The stroke volume index varied; both increases and decreases were observed. On average there was a 3% reduction in the stroke volume index at the completion of the titration period. This modest effect on stroke volume combined with the more appreciable reduction in heart rate caused a significant decrease in cardiac output, with an average fall in cardiac index of 21% by the end of the titration period. There was no concurrently clinically significant change in total peripheral resistance. Thus, the fall in arterial pressure was primarily due to the decline in cardiac output. Both the cardiac index and the stroke volume index returned to control levels within 30 min of termination of the esmolol infusion.
In accordance with the fall in both systolic blood pressure and heart rate there was a significant decrease of 33% in the rate-pressure product ( which lasted up to 10 days. Metoprolol was discontinued at the discretion of the treating physician in one patient because of brief asymptomatic sinus pauses. Two of the three patients in group B who did not enter the maintenance phase because of drug-induced hypotension eventually tolerated low doses of oral metoprolol after their conditions had stabilized clinically and hemodynamically. Their systolic blood pressures at hospital discharge were 90 to 110 mm Hg. The patient who developed postprandial vagal symptoms during the maintenance infusion phase was subsequently started on 50 mg/day atenolol without difficulty.
Discussion
Symptomatic coronary artery disease as manifested as angina or AMI results from an imbalance between myocardial oxygen supply and demand. By reducing heart rate, arterial pressure, and myocardial contractility, important determinants of myocardial oxygen con-THERAPY AND PREVENTION-f3-ADRENERGIC BLOCKADE that, when coupled with the rapid return to the baseline rate after termination of the infusion, is indicative of a clear drug effect. The fall in heart rate was matched by a similar decline in arterial pressure. There was no significant change in left ventricular filling pressure during either the titration or maintenance phases of esmolol infusion, except in the one patient who experienced a sudden ischemic episode during the infusion. This is similar to observations made in several prior studies of /3-blockers in patients with acute ischemia.2-30 34 Even in our seven patients with abnormally elevated pulmonary capillary pressures (. 12 mm Hg), there was no evidence of congestive heart failure or pulmonary edema.
Duration of action. All values for hemodynamic parameters initially influenced by esmolol returned toward baseline within 30 min of terminating the infusion. This is in agreement with prior observations in animals, normal human volunteers, and patients with supraventricular tachycardia.'-4 Serum and tissue esterases are thought to be the prime mechanism of esmolol's "ultra short" (tl/2 = 9 min) duration of action. cardia, hypotension, congestive heart failure, atrioventricular block, or asthma excluded 18% to 28% of otherwise eligible patients.22 24 These patients may, however, have been the very patients most likely to benefit from such therapy. While use of esmolol in such a subset of patients has yet to be reported, its rapid reversal of action may allow the safe initiation of /3-blockade in some of these high-risk patients.
Recent studies suggest that there is a brief period of several hours after acute coronary occlusion during which revascularization may limit eventual size of infarction or reduce mortality. 18, 37, 38 The immediate administration of cardioprotective agents, such as l3-adrenergic blockers, calcium-channel blockers, or other drugs, may prolong the critical time period during which reperfusion, whether thrombolytic, mechanical, or surgical, would be beneficial. Lange et al. ' 
